Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018:53:102-106.
doi: 10.1016/j.ijscr.2018.10.016. Epub 2018 Oct 24.

Synchronous bilateral breast cancer: A case report of heterogeneous estrogen receptor status

Sunny Dhadlie  1 , Joseph Whitfield  2 , Rasika Hendahewa  3
Affiliations

Synchronous bilateral breast cancer: A case report of heterogeneous estrogen receptor status

Sunny Dhadlie et al. Int J Surg Case Rep. 2018.

Abstract

Introduction: Tumour heterogeneity is important in the management of breast cancer. Hormone receptors are established biomarkers for treatment and prognosis of patients with breast cancer. There are three immunohistochemical biomarkers: estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 (HER2). We explore whether heterogeneity in hormone receptor status in synchronous bilateral breast alters therapeutic management.

Case presentation: This case details a 54 year old woman who was referred to our clinic by her general practitioner for investigation of bilateral breast pain that she had for 6 months. On clinical examination pathological nodes were palpated in bilateral axilla. There was left sided nipple inversion with a palpable mass in the upper outer quadrant of approximately 3 cm diameter. On examination of the right breast there was skin tethering of the nipple and 3 masses were palpated, the largest being in the upper inner quadrant at 5 cm diameter. Ultrasound and mammography of bilateral breasts demonstrated advanced bilateral breast cancer with axillary node metastases. Core biopsies demonstrated invasive carcinoma. The right breast lesion was ER negative whilst the left breast lesion was ER positive.

Discussion: In patients with synchronous bilateral breast cancer ER discordance in patients have been associated with higher mortality than ER concordant positive patients and lower mortality than ER concordant negative patients within the first 5 years of surveillance [1].

Conclusion: Heterogeneity in hormone receptor status alters the therapeutic management of patients with synchronous bilateral breast cancer. Both hormone therapy and chemotherapy should be considered in these patients. It is of utmost importance to evaluate the tumor receptor status in cases of synchronous bilateral breast tumour and to assess for change in relation to tumour progression or treatment. Further study in the status change of receptors could open up new treatment modalities.

Keywords: Bilateral breast cancer; Hormone receptors; Oestrogen receptor; Synchronous.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Left core biopsy.
Fig. 2
Fig. 2
Right core biopsy.
Fig. 3
Fig. 3
Left ER.
Fig. 4
Fig. 4
Left PR.
Fig. 5
Fig. 5
Left HER 2.
Fig. 6
Fig. 6
Right ER.
Fig. 7
Fig. 7
Right PR.
Fig. 8
Fig. 8
Right HER2.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Agha R.A., Fowler A.J., Saetta A., Barai I., Rajmohan S., Orgill D.P., for the SCARE Group The SCARE statement: consensus-based surgical case report guidelines. Int. J. Surg. 2016;34:180–186. - PubMed
    1. Turashvili G., Brogi E. Tumor heterogeniety in breast Cancer. Front. Med. 2017;4(227) - PMC - PubMed
    1. Hortobagyi G.N., D’orsi C.J., Edge S.B., Mittendorf E.A., Rugo H.S., Solin L.J. 8th ed. Springer; Chicago: 2017. AJCC Cancer Staging Manual – Breast.
    1. Harris L.N., Ismaila N., Mcshane L.M., Andre F., Collyar D.E., Gonzalez-Angulo A.M. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2016;34:1134–1150. - PMC - PubMed
    1. Lakhani S.R., Ellis I.O., Schnitt S.J., Tan P.H., Van De Vijver M.J., editors. WHO Classification of Tumours of the Breast. France International Agency for Research on Cancer; Lyon: 2012.